Atea announced that its Board has authorized, and will promptly begin executing upon, the repurchase of up to $25M of the Company’s common stock. This authorization reflects the Company’s commitment to return capital to shareholders, while maintaining the flexibility needed to continue funding its global Phase 3 HCV program and positioning Atea for long-term success.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVIR:
- Atea Pharmaceuticals appoints Howard Berman to board of directors
- Atea Pharmaceuticals price target lowered to $6 from $6.20 at Morgan Stanley
- Atea Pharmaceuticals doses first patient in C-BEYOND, Phase 3 study
- Atea Pharmaceuticals cuts 25% of workforce, exploring partnerships
- Radoff-JEC Group nominates candidates to Atea Pharmaceuticals board